Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

This review aims to assess the benefits and harms of GLP-1 receptor agonists to treat diabetes in people with CKD.

This is a protocol.

Health topics:

Endocrine & metabolic > Diabetes > Diabetic kidney disease

Published:

17 April 2023

Authors:

Natale P, Palmer SC, Tunnicliffe DJ, Toyama T, Strippoli GFM

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Natale P, Palmer SC, Tunnicliffe DJ, Toyama T, Strippoli GFM. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 4. Art. No.: CD015849. DOI: 10.1002/14651858.CD015849.